Biogen Idec patents expiration
1. Spinraza patents expiration
SPINRAZA's oppositions filed in EPO
Can you believe SPINRAZA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6166197 | BIOGEN IDEC | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
Dec, 2017
(6 years ago) | |
| US7101993 | BIOGEN IDEC | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(7 months ago) | |
| US7838657 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Jul, 2027
(3 years from now) | |
| US8361977 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing |
May, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6210892 | BIOGEN IDEC | Alteration of cellular behavior by antisense modulation of mRNA processing |
Oct, 2018
(5 years ago) | |
| US10266822 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(1 year, 7 months from now) | |
| US8110560 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(1 year, 7 months from now) | |
| US9717750 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jun, 2030
(6 years from now) | |
| US8980853 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Nov, 2030
(6 years from now) | |
| US9926559 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jan, 2034
(9 years from now) | |
| US10436802 | BIOGEN IDEC | Methods for treating spinal muscular atrophy |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-226) | May 14, 2021 |
| Orphan Drug Exclusivity(ODE-127) | Dec 23, 2023 |
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
NCE-1 date: 23 December, 2020
Market Authorisation Date: 23 December, 2016
Treatment: Treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; Treatment of spinal muscular atrophy; Treatment of infantile-onset spinal muscular atrophy
Dosage: SOLUTION;INTRATHECAL
More Information on Dosage
SPINRAZA family patents
